Crucial role of group IIA phospholipase A(2) in oleic acid-induced acute lung injury in rabbits.
Group IIA secretory phospholipase A(2) (sPLA(2)) has been implicated in a variety of inflammatory diseases including acute lung injury (ALI); however, the role of sPLA(2) in this disorder remains unclear. The aim of the present investigation was to examine the role of this enzyme in a model of ALI induced by oleic acid (OA) in rabbits by testing human group IIA phospholipase A(2) (PLA(2)) inhibitor, S-5920/LY315920Na. Experimental groups consisted of a saline control group (n = 8), an OA control group (n = 10) infused intravenously with OA (0.1 ml/kg/h for 2 h), and three groups given OA + S-5920/LY315920Na (three different doses, n = 8, respectively). Infusion of OA provoked pulmonary hemorrhage and edema formation, protein leakage, and massive neutrophil infiltration, resulting in severe hypoxemia and impaired lung compliance. PLA(2) activity was detected in the bronchoalveolar lavage fluid (BALF), but not plasma, which correlated well with severity of lung injury in this model. Pretreatment with S-5920/LY315920Na diminished the OA-induced PLA(2) activity in the BALF and dose-dependently attenuated the previously described lung injury induced by OA, accompanied by protection against lung surfactant degradation and production of thromboxane A(2) (TXA(2)) and leukotriene B(4) (LTB(4)). S-5920/LY315920Na also inhibited the OA-induced production of interleukin-8 (IL-8), both in plasma and BALF. Thus, sPLA(2) appears to play a key role in OA-induced lung injury, suggesting that the group IIA PLA(2) inhibitor may be a promising agent for patients with acute respiratory distress syndrome (ARDS).
Furue
S
S
Department of Anesthesiology, Kobe University School of Medicine, Kobe, Japan.
Kuwabara
K
K
Mikawa
K
K
Nishina
K
K
Shiga
M
M
Maekawa
N
N
Ueno
M
M
Chikazawa
Y
Y
Ono
T
T
Hori
Y
Y
Matsukawa
A
A
Yoshinaga
M
M
Obara
H
H
D000085:Acetates / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D002199:Capillary Permeability; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology; D015633:Extravascular Lung Water / Q000502:physiology; D054501:Group II Phospholipases A2; D007211:Indoles / Q000493:pharmacokinetics / Q000494:pharmacology; D016209:Interleukin-8 / Q000378:metabolism; D007651:Keto Acids; D007975:Leukotriene B4 / Q000378:metabolism; D008168:Lung / Q000098:blood supply / Q000473:pathology; D008170:Lung Compliance; D008297:Male; D019301:Oleic Acid; D010100:Oxygen / Q000097:blood; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D010743:Phospholipids / Q000032:analysis; D011654:Pulmonary Edema / Q000503:physiopathology; D011817:Rabbits; D012128:Respiratory Distress Syndrome / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology*; D013928:Thromboxane A2 / Q000378:metabolism
D000085:Acetates; D004791:Enzyme Inhibitors; D007211:Indoles; D016209:Interleukin-8; D007651:Keto Acids; D010743:Phospholipids; D007975:Leukotriene B4; C117948:varespladib; D019301:Oleic Acid; D013928:Thromboxane A2; D010741:Phospholipases A; D054501:Group II Phospholipases A2; D010100:Oxygen